Why did BioArctic enter into a new research collaboration with Eli Lilly?

BioArctic entered the collaboration to combine its proprietary BrainTransporter technology with an undisclosed neurodegeneration drug candidate from Eli Lilly. The partnership aims to generate a new treatment capable of crossing the blood-brain barrier effectively.

What are the financial terms of the agreement between BioArctic and Eli Lilly?

BioArctic will receive an upfront payment of $30 million from Eli Lilly. The company is also eligible to receive up to $770 million in additional milestone payments plus tiered mid-single digit royalties on future product sales.

How is development responsibility divided between BioArctic and Eli Lilly?

Eli Lilly will assume full responsibility for the global clinical development and commercialization of the resulting drug candidate. BioArctic will focus on initial generation of the drug candidate using its proprietary transport platform.

What does this agreement mean for the platform rights of BioArctic?

This deal marks the fourth active collaboration for the BrainTransporter platform developed by BioArctic. The company retains all independent rights to utilize its proprietary delivery platform outside the scope of these four specific partner agreements.

What are the expectations regarding clinical success for this BioArctic project?

BioArctic stated that the project involves an investigational agent currently in development. The company notes there is no independent assurance of future clinical success or regulatory approval for the drug candidate.

Image for illustrative purposes only. Not a real photo.

BioArctic partners with Lilly in $770 million deal

Written by Jon CuthbertPublished Jun 22, 2026, 8:01 AM

BioArctic entered a research collaboration with Eli Lilly to develop a new neurodegeneration drug candidate.
The agreement includes a $30 million upfront payment and up to $770 million in milestone fees.
The partnership leverages BioArctic's proprietary platform to enhance blood-brain barrier drug delivery.

BioArctic partnered with Eli Lilly (NYSE:LLY) on a neurodegeneration drug deal potentially worth $770 million.

This transaction expands the firm's commercial pipeline compared to standalone development programs tracked during previous years.

"I'm excited by today's announcement and proud that a large pharmaceutical company sees potential in our proprietary BrainTransporter technology," said BioArctic CEO Gunilla Osswald.

The biopharma company will receive $30 million upfront alongside tiered mid-single digit royalties on global sales.

The newly executed deal represents the fourth corporate collaboration utilizing this proprietary brain transport platform.

Outside of these four specific partner agreements, the Swedish enterprise retains all independent platform rights.

BioArctic partners with Lilly in $770 million deal

Frequently asked questions

Assets related to this article